Skip to main content

Table 2 Unadjusted and adjusted determinants of chemotherapy initiation within 30 days of Kaposi’s sarcoma (KS) diagnosis among HIV-infected patients newly diagnosed with KS between 2009 and 2012 in a large community-based primary care network in Kenya

From: Real-world use of chemotherapy for Kaposi’s sarcoma in a large community-based HIV primary care system in Kenya

 UnadjustedAdjusted Model 1aAdjusted Model 2a
CharacteristicRisk Ratio
(95% CI)
P valueRisk Ratio
(95% CI)
P valueRisk Ratio (95% CI)P value
Age, years
  ≤ 30Ref. Ref. Ref. 
 30–341.02 (0.72–1.45)0.9081.04 (0.64–1.68)0.8721.00 (0.60–1.66)0.997
 35–390.66 (0.42–1.03)0.0680.72 (0.41–1.25)0.2420.62 (0.34–1.13)0.119
  ≥ 400.81 (0.55–1.19)0.2850.85 (0.51–1.39)0.5110.83 (0.49–1.41)0.489
Gender
 WomenRef. Ref. Ref. 
 Men1.10 (0.82–1.49)0.5201.10 (0.75–1.62)0.6231.04 (0.69–1.57)0.838
Chemotherapy indications
 1 chemotherapy indicationRef. Ref. Ref. 
 2 chemotherapy indications1.75 (1.26–2.44)0.0011.82 (1.19–2.79)0.0061.86 (1.20–2.87)0.005
  ≥ 3 chemotherapy indications2.18 (1.58–3.01)< 0.0012.30 (1.46–3.60)< 0.0012.43 (1.51–3.91)< 0.001
CD4+ T cells, count/μl
  > 350Ref. Ref. Ref. 
 201–3501.55 (0.93–2.59)0.0911.61 (0.85–3.06)0.1431.54 (0.80–2.98)0.200
 51–2001.65 (1.03–2.63)0.0361.74 (0.97–3.11)0.0631.86 (1.03–3.37)0.040
  < 501.11 (0.60–2.07)0.7311.04 (0.49–2.20)0.9131.04 (0.49–2.23)0.909
 CD4 unknown1.06 (0.65–1.74)0.7201.07 (0.60–1.92)0.8201.03 (0.56–1.89)0.921
Education
 NoneRef.   Ref. 
 Primary1.00 (0.55–1.80)0.990  0.85 (0.39–1.85)0.689
 Secondary1.18 (0.64–2.19)0.590  1.09 (0.48–2.44)0.842
 Tertiary1.31 (0.56–3.07)0.540  1.20 (0.38–3.82)0.760
Travel time to clinic
  < 30 minRef.   Ref. 
 30–59 min1.05 (0.67–1.65)0.837  1.06 (0.60–1.87)0.835
 1–2 h1.22 (0.78–1.91)0.387  1.18 0.67–2.07)0.567
  > 2 h1.42 (0.91–2.20)0.119  1.37 (0.76–2.45)0.295
Water piped into home
 NoRef.   Ref. 
 Yes1.11 (0.74–1.68)0.604  1.14 (0.65–1.97)0.652
  1. aall variables adjusted for all other variables in column